Alcidion Group Limited · ASX:ALC
Alcidion — Investor Presentation (August 2016)
57 slides from Alcidion's investor presentation, Aug 31, 2016
Slide 1: Alcidion Group Limited Investor Update
For personal use only Alcidion Group Limited Investor Update August 2016
Slide 2: Disclaimer
DISCLAIMER Disclaimer For personal use only This presentation has been prepared by Alcidion Group Limited (the "Company"). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the c
Slide 3: Part 1: Shareholder Update
For personal use only PART 1: SHAREHOLDER UPDATE ● Shareholder Update – Introduction to panellists. – Alcidion Value Proposition. – Achievements since listing. – Strategic Direction. – Investor Relations update. – Commercialisation Strategy. – North American Market Entry.
Slide 4: Part 2: Alcidion Overview
For personal use only PART 2: ALCIDION OVERVIEW ● Western Health Case Study ● Market Opportunity – Global State of Health IT. – EMR Adoption Model. ● Q&A ● Product Overview1 – Miya Architecture. – Miya Patient Flow. – Miya Access. – Miya Mobile. – Miya ED. – Miya Orders. – Miya Clinic. 1 Not present
Slide 5: Shareholder Update
For personal use only Update Shareholder
Slide 6: Alcidion key facts and ownership
ASX Ticker ALC Market Capitalisation $35m For personal use only 40% Founders 15% BlueSky Private Equity Ownership 9% Owned by Employees 6% Allure Capital Share Price 5.80c Cash on hand $5.84m Enterprise Value $29m Shares on Issue 603m Employees 32 x FTE Revenues FY16 $4.02m Cumulative R&D Investment
Slide 7: Executive Directors
For personal use only EXECUTIVE DIRECTORS Chief Medical Officer Chief Executive Officer Executive Director Prof. Malcolm Pradhan Mr. Ray Blight Mr. Nathan Buzza • Formal qualifications in medicine • Formal qualifications include a Bachelor of • Former founder & CEO of Clinical Middleware complimente
Slide 8: Non-Executive Directors
For personal use only NON-EXECUTIVE DIRECTORS Non-Executive Director Non-Executive Director Non-Executive Director Mr. Brian Leedman Mr. Nick Dignam Mr. Josh Puckridge • Formal qualifications include a Bachelor of • Formal qualifications include a Bachelor of • Formal qualifications include a Bachel
Slide 9: Where We Have Come From?
For personal use only WHERE WE HAVE COME FROM ?
Slide 10: Alcidion Overview
For personal use only ALCIDION OVERVIEW ● Alcidion is a provider of intelligent informatics for high performance healthcare: – Safer for patients because clinicians are alerted to emerging clinical risk; – Faster delivery of care because service barriers are identified and; – Improved productivity b
Slide 11: What Does Alcidion Do?
WHAT DOES ALCIDION DO ? ● Hospitals are built upon a complex eco-system For personal use only of disparate Clinical Information Systems. ● Alcidion’s Miya platform integrates disparate Clinical Information Systems to identify emerging clinical risk and push this clinical intelligence to the care tea
Slide 12: What Is the Miya Platform?
For personal use only WHAT IS THE MIYA PLATFORM ? ● An E-Health guidance platform: – to consolidate clinical information and patient data from multiple sources across the hospital – focused on patient clinical risk and surfacing clinical data relevant to the patient’s current clinical context – to p
Slide 13: Highlights FY16
For personal use only HIGHLIGHTS FY16 ● As of 30 June 2016 the Company held $5.65m in cash. ● As of 31 July 2016 the Company held $6.51m in cash, excluding the provision for the $1m R&D Tax Incentive. ● At the completion of the RTO of Naracoota Resources Limited, the Company held $6.758m in cash. ●
Slide 14: Highlights FY16
For personal use only HIGHLIGHTS FY16 ● The Company appointment of Mr. Brian Leedman to the Board. ● The Company is presently re-aligning its resources towards increasing expenditure in Sales & Marketing and reducing expenditure in R&D. ● Alcidion made significant progress over the course of the pas
Slide 15: Reverse Takeover Update
REVERSE TAKEOVER UPDATE ● Alcidion listed at 5.40c on the 29/2/2016. For personal use only ● When Alcidion listed on the ASX, the company had 602m shares on issue, consisting of: – 400m Shares Alcidion Shareholders. – 138m Shares Original NRR Shareholders. – 64m Shares $2.00m Capital Raise. ● The Co
Slide 16: Multiple Key Drivers of Market Growth
MULTIPLE KEY DRIVERS OF MARKET GROWTH Customer Demand Technology Demographics / Economy For personal use only ● Increased cost pressure drives ● Growing demand for integrated ● Demographics the need to quantifiable ROI. Clinical Decision Support • Rise in ageing population ● Demand for systems drive
Slide 17: Strategic Direction
For personal use only STRATEGIC DIRECTION ● Transition the company from a ● Rebalance the organization from ● Target a total of 40 hospitals private entity to a publicly listed its core focus of engineering to a across Australia and New business and secure funding to balanced business with a Zealand
Slide 18: Investor quote: Blue Sky Private Equity
For personal use only “At BlueSky we meticulously evaluate every opportunity. Alcidion ticked all the boxes: Mobile, Healthcare, Information Technology, coupled with an internationally recognized Management Team.” Nick Dignam Investment Director Blue Sky Private Equity
Slide 19: Investor quote: Allure Capital
“What really struck me about Alcidion For personal use only was the deep seated passion of the founders to fix healthcare – coupled with their impeccable qualifications” Nathan Buzza Allure Capital
Slide 20: Investor Relations Update
For personal use only INVESTOR RELATIONS UPDATE ● Alcidion has five primary blocks of shareholders: – The Alcidion Corporation Shareholders. – New shareholders investing in the medical informatics business. – The original NRR Shareholders. – The shareholders from the $2m Capital Raise. – Day (Short
Slide 21: Investor Relations Update
INVESTOR RELATIONS UPDATE ● As part of the RTO of ALC, NRR Raised For personal use only $2.00m through a full form prospectus and the issue of 64.52m shares at 3.10c per share. ● Since Alcidion listed on the ASX, the following reflects the shareholder movement: – Of the 400m shares issued to the Alc
Slide 22: North American Commercialization Overview
NORTH AMERICAN COMMERCIALIZATION OVERVIEW ● Alcidion is committed to expanding its operations For personal use only into the United States, as quickly as commercially viable. ● 95% of North American Hospitals are yet to achieve EMRAM level 7 and as a result this would appear to be a decade long oppo
Slide 23: Commercialisation Strategy
COMMERCIALISATION STRATEGY Systematically progress through the continuum of health in For personal use only Australia / New Zealand. ● Healthcare ICT Consultants. ● Strategic Partners. ● Hospitals. ● State Health Departments. ● District Health Boards. ● Local Health Boards. ● Private Hospital Groups
Slide 24: Commercialisation Strategy: Target Demographics
COMMERCIALISATION STRATEGY For personal use only Target Demographics ● ~8 x Health Departments. ● ~10 x Major Healthcare Consultancy Firms. ● ~15 x Major Strategic Partners. ● ~262 x Hospitals with more than 100 beds. ● ~111 x Emergency Departments. ● ~30 x FUJIFILM Synapse Customers (AU). Initial f
Slide 25: Customer testimonial: Western Health
For personal use only “The systems assists in safe and effective patient care by identifying patients who are at risk” Marcus Storey Nurse Unit Manager Western Health
Slide 26: Customer testimonial: Western Health
For personal use only “This has skyrocketed the efficiency in patient care as well as the safety” Professor Tissa Wijerante Consulting Neurologist Director of the Stroke & Neuroscience Unit Western Health
Slide 27: Customer testimonial: Western Health
For personal use only “You’ll see nearly all of the clinical, executive and divisional directors walking around with the bed management views on their iPads, and the same with the bed management staff, the quality managers, the NUMs and any staff that help move the patients around.” Jason Whakaari E
Slide 28: For personal use only
“Rather than creating an electronic version of the existing patient journey boards, we have created an For personal use only e-health guidance system.”
Slide 29: Customer Testimonial
For personal use only CUSTOMER TESTIMONIAL
Slide 30: Market Opportunity
For personal use only Market Opportunity
Slide 31: Why Is Digital Health Such an Exciting Investment Opportunity?
WHY IS DIGITAL HEALTH SUCH AN EXCITING INVESTMENT OPPORTUNITY ? ● The global population is aging, resulting in a dramatic For personal use only and unparalleled increase in population, complex patients with multiple co-morbidities. ● The United States spends 18% of GDP on Healthcare, representing ov
Slide 32: What Exactly Is Digital Health?
WHAT EXACTLY IS DIGITAL HEALTH ? Technology only Consumer Centric Technologies Practice Centric Technologies Data Storage Applications Data Transmission Medical Records Connect Prevention Analytics Schedule Education use Chat Communicate Deliver Manage Intelligence Verify Outsource Share Data Collec
Slide 33: The Stars Are Aligning for Digital Health
THE STARS ARE ALIGNING FOR DIGITAL HEALTH ● Global adoption of the “Electronic Medical Records For personal use only Adoption Model (EMRAM)”, supported by government funding. ● The rise of interoptability and global standards. ● Mobile Health technology is growing from $USD6.9b market to $USD23b mar
Slide 34: EMR Adoption Model
EMR ADOPTION MODEL EMRAM STAGE For personal use only EMR 7 STAGE ADOPTION 6 STAGE MODEL 5 STAGE Complete EMR, CCD transactions to Physician 4 share data; Data STAGE documentation warehousing; Data (structured continuity with ED, 3 templates), full ambulatory, OP STAGE CDSS (variance & compliance), 2
Slide 35: Cross Regional EMRAM Score Distribution
CROSS REGIONAL EMRAM SCORE DISTRIBUTION For personal use only 96.30% of the 8,000 Hospitals in the United States are yet to reach EMRAM Stage 7
Slide 36: Questions?
For personal use only QUESTIONS ?
Slide 37: Product Overview
For personal use only Product Overview
Slide 38: Product Offering
For personal use only PRODUCT OFFERING Mitigate risks and streamline your Outpatient Department Clinical Referral Results Electronic Department Clinical Dashboard & Management Management Journey Boards Metrics Dashboards ED Whiteboards System Missed Result Miya Mobile: Miya Miya Results Miya ID Trac
Slide 39: Alcidion's Miya Platform
For personal use only ALCIDION’S MIYA PLATFORM
Slide 40: Miya Overview
For personal use only MIYA OVERVIEW
Slide 41: Product Roadmap
For personal use only PRODUCT Product Roadmap Under Alpha Release Beta Release Pilot Commercial Development Installation iCVIS Miya Patient Flow Miya Access Miya Mobile Order Sets Smartforms Miya ED Miya Clinic Miya Metrics Miya AI
Slide 42: Mobility: Native iOS App
For personal use only MOBILITY: NATIVE IOS APP
Slide 43: Smartforms
For personal use only SMARTFORMS
Slide 44: Vision of the Future: Mobile Smartforms
VISION OF THE FUTURE: MOBILE SMARTFORMS For personal use only
Slide 45: Miya Results Viewing
For personal use only MIYA RESULTS VIEWING
Slide 46: Miya ED
MIYA ED “ For personal use only Miya ED provides a set of clinical dashboards that allow your Emergency Department team to have a dedicated display for risk management by augmenting your existing EDIS. Miya ED can be used to highlight key risks, activate best practice guidance for common problems an
Slide 47: Product Overview: Miya ED
PRODUCT OVERVIEW MIYA ED For personal use only ● Miya ED adds value to existing ED information systems and delivers significant service performance improvement, for example, with Miya ED in the Northern Territory: – Patient treatment commences an hour earlier – early intervention leads to faster rec
Slide 48: Miya Patient Flow
For personal use only MIYA PATIENT FLOW “ Miya Patient Flow is an e-health guidance system that optimises the patient journey for your patients by integrating powerful electronic journey boards, a mobile EMR, Mobile Bed Management and an intelligent monitoring system. ”
Slide 49: Product Overview: Miya Patient Flow
PRODUCT OVERVIEW MIYA PATIENT FLOW ● Miya Patient Flow guides the care team in optimising For personal use only a patient’s journey through the hospital services. ● Miya Patient Flow supports the efficient use of hospital beds/resources whilst providing effective clinical outcomes for patients – it
Slide 50: For personal use only
For personal use only Patient Rows updated when patients are admitted, transferred or discharged Rows are configurable if required Summary metrics: patients waiting in ED, boarders, outliers
Slide 51: Miya Mobile
For personal use only MIYA MOBILE
Slide 52: Miya Access (Bed Management)
For personal use only MIYA ACCESS (BED MANAGEMENT)
Slide 53: Miya Orders
For personal use only MIYA ORDERS
Slide 54: Miya ED Mobile
For personal use only MIYA ED MOBILE
Slide 55: Miya Clinic
For personal use only MIYA CLINIC “ Miya Clinic Outpatient Software and Referral Management System saves clinical time and effort spent searching for relevant data during clinics, and optimises your outpatient processes from referral through to discharge ensuring that patients receive best practice,
Slide 56: Product Overview: Miya Clinic
PRODUCT OVERVIEW MIYA CLINIC ● Miya Clinic provides clinical decision support for Doctors For personal use only treating ambulatory patients in the Outpatient services of a hospital – Outpatient services include minor procedures, medical consultations/diagnosis and allied health interventions (e.g.
Slide 57: Questions?
For personal use only QUESTIONS ?